Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Low-alcohol Red Wine Reduced PAH Symptoms in Rats

Regularly consuming low-alcohol red wine reduced signs of pulmonary arterial hypertension (PAH) in a rat model of the disease, a study shows. “The results of this study suggest that chronic moderate consumption of RARW [reduced-alcohol red wine] or its components may represent a promising new protective strategy to limit…

Bayer Doles Out $1M of Its PHAB Awards to 7 Research Projects

As part of the company’s Pulmonary Hypertension Accelerated Bayer (PHAB) Awards, Bayer is giving a total of $1 million to seven research projects related to pulmonary hypertension. The awards are aimed at projects focused on pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), which makes the…

Apabetalone Fares Well in Early Clinical Trial

Apabetalone (RVX-208), Resverlogix‘s experimental treatment for pulmonary arterial hypertension (PAH), was well-tolerated in a small clinical trial, the company announced. The trial met its primary goal of adding apabetalone to standard care to improve pulmonary vascular resistance (PVR), a measure that reflects the internal resistance to blood…

Breast Milk Linked to Better Heart Health in Premature Babies

For premature babies who are at high risk of pulmonary hypertension (PH) and other cardiovascular complications, consuming human breast milk in the first year of life is associated with better heart function, a new study found. “Preterm infants have abnormal heart function,” Afif EL-Khuffash, MD, the study’s lead author, said…

Uptravi IV Offers Important Option for Patients, Exec Says

In late July, the U.S. Food and Drug Administration (FDA) approved a new formulation of Janssen‘s Uptravi (selexipag) for use by people with pulmonary arterial hypertension (PAH). Uptravi already was available as an oral tablet. The new formulation is intravenous (IV) — meaning it is administered by an…

FDA Approves IV Form of Uptravi as Short-term Option to Oral Therapy

The U.S. Food and Drug Administration (FDA) has approved an intravenous form of Uptravi (selexipag) — one infused directly into the bloodstream — for people with pulmonary arterial hypertension (PAH) temporarily unable to take oral medicines. The new intravenous, or IV, formulation is intended to prevent treatment interruptions in adults…

Inflammatory TIFA Protein Elevated in PAH

A protein called TIFA is elevated in the blood cells of people with pulmonary arterial hypertension (PAH), suggesting this protein is involved in the biological processes that drive the disease, according to a new study. The findings were published in the journal Scientific Reports, in the study, “…

National Broadcast Series Focuses on PAH

An upcoming series of educational virtual events for people with pulmonary arterial hypertension (PAH) and their caregivers will offer insights and perspectives about how to manage life with PAH. The National Broadcast Series will include three talks from August to October. Each of the one-hour talks is scheduled to…

Dosing Begins in Phase 1 Trial of Inhaled Imatinib

Dosing has begun in a clinical trial testing AER-901, Aerami Therapeutics‘ inhaled formulation of imatinib, which is being investigated as a potential treatment for pulmonary arterial hypertension (PAH). “We are pleased to announce that the dosing of subjects in our Phase 1 trial is ongoing and that we expect to…


A Conversation With Rare Disease Advocates